UWorld Mental Health Practice Test

The primary assessment focus when evaluating a client with moderate Alzheimer's disease on memantine is to determine improvements in the ability to perform activities of daily living (ADLs). Memantine is an NMDA receptor antagonist that is used to manage symptoms of Alzheimer's disease, particularly in moderate to severe stages. While it may help stabilize cognitive function and potentially improve some cognitive skills, the most significant indicator of treatment efficacy is typically reflected in the client's functional abilities. By assessing the improvement in ADLs, the nurse can gauge how the treatment is impacting the patient's daily life and overall quality of life. An enhancement in these skills shows that the medication may be helping to manage symptoms better and enable the client to maintain independence in their routine tasks. Other options, such as indications that disease progression has stopped or experiencing rapid improvement in cognitive functioning, might lead to unrealistic expectations, as memantine does not halt disease progression nor does it provide rapid cognitive recovery. Furthermore, the possibility of reversing Alzheimer’s disease goes beyond the current capabilities of available treatments. Therefore, focusing on the improvement of ADLs provides a more realistic and practical assessment of the treatment's effectiveness in a client with moderate Alzheimer's disease.